Suppr超能文献

早期肝细胞癌组织学诊断的候选分子标志物

Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma.

作者信息

Sakamoto Michiie, Mori Taisuke, Masugi Yohei, Effendi Kathryn, Rie Irie, Du Wenlin

机构信息

Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

出版信息

Intervirology. 2008;51 Suppl 1:42-5. doi: 10.1159/000122603. Epub 2008 Jun 10.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. HCC occurs mainly in chronically diseased livers, e.g. following hepatitis B and C infection. These high-risk patients are closely followed up, and increasing numbers of small equivocal lesions are detected by imaging diagnosis. They are now widely recognized as precursor or early-stage HCCs and are classified as dysplastic nodule or early HCC. These lesions lack typical imaging and histology of ordinary HCC and do not show elevated serum markers of alpha-fetoprotein and PIVKA-II, for example. Molecular analysis of these lesions would help to develop molecular markers for objective histological diagnosis of early HCC and possibly new serum markers for early detection of HCC. It has been reported that HSP70, CAP2, glypican 3 and glutamine synthetase could serve as molecular markers for early HCC. Further analysis is expected to evaluate their usefulness in routine pathological diagnosis including biopsy diagnosis and also as serum markers for early detection of HCC.

摘要

肝细胞癌(HCC)是最常见的恶性肿瘤之一。HCC主要发生在慢性病变的肝脏中,例如在乙型和丙型肝炎感染之后。这些高危患者会受到密切随访,并且通过影像学诊断发现的可疑小病变数量不断增加。它们现在被广泛认为是HCC的前驱病变或早期病变,并被归类为发育异常结节或早期HCC。这些病变缺乏普通HCC典型的影像学和组织学特征,例如不显示血清甲胎蛋白和异常凝血酶原-II升高。对这些病变进行分子分析将有助于开发用于早期HCC客观组织学诊断的分子标志物,并可能有助于开发用于早期检测HCC的新血清标志物。据报道,热休克蛋白70(HSP70)、钙蛋白酶2(CAP2)、磷脂酰肌醇蛋白聚糖3(glypican 3)和谷氨酰胺合成酶可作为早期HCC的分子标志物。期望进一步分析以评估它们在包括活检诊断在内的常规病理诊断中的实用性,以及作为早期检测HCC的血清标志物的实用性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验